NCT00419783View on ClinicalTrials.gov

A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Healthy
Interventions
DRUG

bilastine

20 mg tablets.

DRUG

Bilastine

100 mg (5 tablets of 20 mg)

DRUG

Bilastine & Ketoconazole

1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet

DRUG

Moxifloxacin

1 capsule containing moxifloxacin 400 mg tablet

DRUG

Placebo

Placebo tablets

Trial Locations (1)

85044

MDS Pharma Services, Phoenix

Sponsors

Lead Sponsor

Faes Farma, S.A.
All Listed Sponsors
lead

Faes Farma, S.A.

INDUSTRY

NCT00419783 - A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine | Biotech Hunter | Biotech Hunter